Oxatomide modifies methacholine- and exercise-induced bronchoconstriction in asthmatic children

Area of Science:

• Pharmacology
• Pediatric Pulmonology
• Allergy and Immunology

Background:

• Oxatomide is a chemical compound structurally similar to calcium antagonists.
• It functions as a potent inhibitor of allergic mediator release and effects.
• Oxatomide prevents histamine release by modulating intracellular and extracellular calcium levels.

Purpose of the Study:

• To investigate the effects of oxatomide on methacholine-induced bronchoconstriction in asthmatic children.
• To evaluate the impact of oxatomide on exercise-induced bronchoconstriction in pediatric asthma patients.

Main Methods:

• A double-blind, placebo-controlled study involving asthmatic children.
• Methacholine challenges were administered after oral oxatomide (0.88 mg/kg) or placebo.
• Exercise challenges were conducted following oral administration of oxatomide (1.5 mg/kg) or placebo.

Main Results:

• Oxatomide significantly improved respiratory thresholds in methacholine challenges (log PC20: 6.65 vs. 5.74 µg/mL, P < .05).
• Oxatomide demonstrated acute bronchodilation, improving FEV1 by an average of 6.1% during exercise challenges.
• The maximal percentage fall in FEV1 was significantly reduced with oxatomide (13.5%) compared to placebo (22%, P < .05).

Conclusions:

• Oxatomide effectively reduces nonspecific bronchial hyperresponsiveness in children with asthma.
• The findings suggest oxatomide is beneficial in managing asthma-related airway hyperreactivity.
• Oxatomide's mechanism involves inhibiting calcium influx and release, impacting allergic mediator pathways.